Last $0.17 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 07/24/14 All times are local (Market data is delayed by at least 15 minutes).

urologix inc (ULGX) Snapshot

Open
$0.14
Previous Close
$0.17
Day High
$0.17
Day Low
$0.14
52 Week High
08/12/13 - $0.38
52 Week Low
12/23/13 - $0.11
Market Cap
3.6M
Average Volume 10 Days
12.2K
EPS TTM
$-0.26
Shares Outstanding
21.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for UROLOGIX INC (ULGX)

Related News

No related news articles were found.

urologix inc (ULGX) Related Businessweek News

No Related Businessweek News Found

urologix inc (ULGX) Details

Urologix, Inc. develops, manufactures, and markets non-surgical, office-based therapies for the treatment of the symptoms and obstruction resulting from benign prostatic hyperplasia (BPH). The company offers Cooled ThermoTherapy product line, which includes the CoolWave and Targis Control Units, and the CTC Advance catheter for the production of targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. It also distributes Prostiva RF Therapy Systems, which delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra and relieves BPH voiding symptoms. The company distributes its products to urologist offices, ambulatory surgery centers, and hospitals through its direct sales force and local distributors in the United States and internationally. Urologix, Inc was founded in 1991 and is based in Minneapolis, Minnesota.

95 Employees
Last Reported Date: 09/20/13
Founded in 1991

urologix inc (ULGX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $200.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $135.0K
Executive Vice President of Sales and Marketi...
Total Annual Compensation: $210.0K
Compensation as of Fiscal Year 2013.

urologix inc (ULGX) Key Developments

Urologix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014

Urologix, Inc. reported earnings results for the third quarter and nine months ended March 31, 2014. The company has reported that net loss for the third quarter ended March 31, 2014 was $1.66 million, or $0.08 loss per share, compared to a net loss of $1 million, or $0.05 loss per share, for the same quarter ended March 31, 2013. Sales for the third quarter ended March 31, 2014 were $3.36 million, compared to $4.08 million for the same quarter ended March 31, 2013. Net loss for the nine months ended March 31, 2014 was $4.08 million, or $0.19 loss per share, compared to a net loss of $3.04 million, or $0.15 loss per share, for the same period ended March 31, 2013. Sales for the nine months ended March 31, 2014 were $10.94 million, compared to $12.40 million for the same period ended March 31, 2013.

Urologix, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended March 31, 2014

Urologix, Inc. reported unaudited earnings results for the third quarter and nine months ended March 31, 2014. Third quarter fiscal year 2014 revenue totaled $3.4 million, down 12% sequentially and down 18% compared to the third quarter of fiscal year 2013. The revenue declines sequentially and compared to the third quarter of fiscal year 2013 were due to lower volume of units sold in both product lines. The company reported a net loss of $1.7 million, or $0.08 per diluted share, compared to a net loss of $1.0 million, or $0.05 per diluted share, in the third quarter of fiscal year 2013. The increase in net loss in the third quarter of fiscal year 2014 was primarily due to the higher cost of goods related to the $739,000 non-cash charge associated with the write down of Prostiva capital equipment inventory. The company reported operating loss of $1,467,000, loss before income taxes of $1,646,000 against operating loss of $844,000, loss before income taxes of $988,000 a year ago. For the nine months, the company reported sales of $10,941,000, operating loss of $3,522,000, loss before income taxes of $4,037,000, net loss of $4,083,000 or $0.19 per diluted share against sales of $12,405,000, operating loss of $2,640,000, loss before income taxes of $2,997,000, net loss of $3,045,000 or $0.15 per diluted share a year ago. Net cash used for operating activities was $1,439,000 against $550,000 a year ago. Purchases of property and equipment were $28,000 against $55,000 a year ago.

Urologix, Inc. to Report Q3, 2014 Results on May 06, 2014

Urologix, Inc. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Standard Time on May 06, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ULGX:US $0.17 USD 0.00

ULGX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $13.10 USD -0.16
Medifocus Inc C$0.13 CAD -0.025
Olympus Corp ¥3,660 JPY +95.00
Uroplasty Inc $2.60 USD -0.03
View Industry Companies
 

Industry Analysis

ULGX

Industry Average

Valuation ULGX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact UROLOGIX INC, please visit www.urologix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.